IHL used to be ASX only. Then thought listing on Nasdaq will give them the “right valuation” because “Americans value biotechs because they are smart investors”. The US listed ADR (IXHL) didn’t get any high valuation. After nearly 2 years they decided to delist from ASX and become a purely USA listed company for “better valuation” reasons. If a management is purely focused on their SP and not recognising that the world went thru a “Biotech winter” for 3 years, that is not a management I want to be invested in, and I sold out after their decision to delist from ASX.
I hope CU6 doesn’t go down this path.
JIMHO.
CU6 - General discussion, page-248
-
- There are more pages in this discussion • 236 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.67 |
Change
-1.060(12.1%) |
Mkt cap ! $2.451B | |||
| Open | High | Low | Value | Volume |
| $8.62 | $8.68 | $7.67 | $13.44M | 1.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21192 | $7.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.72 | 59 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |